These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8005192)

  • 1. Plasma levels of oxybutynine chloride in children.
    Autret E; Jonville AP; Dutertre JP; Bertiere MC; Robert M; Averous M; Couet W
    Eur J Clin Pharmacol; 1994; 46(1):83-5. PubMed ID: 8005192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability.
    Halaska M; Ralph G; Wiedemann A; Primus G; Ballering-Brühl B; Höfner K; Jonas U
    World J Urol; 2003 May; 20(6):392-9. PubMed ID: 12811500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia.
    Kasabian NG; Vlachiotis JD; Lais A; Klumpp B; Kelly MD; Siroky MB; Bauer SB
    J Urol; 1994 Apr; 151(4):944-5. PubMed ID: 8126833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Oxybutynin chloride in pediatrics: extenuating circumstances].
    Aubert D
    Arch Fr Pediatr; 1988 May; 45(5):375-6. PubMed ID: 3415420
    [No Abstract]   [Full Text] [Related]  

  • 5. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of intravesical oxybutynin chloride in children with neurogenic bladder.
    Greenfield SP; Fera M
    J Urol; 1991 Aug; 146(2 ( Pt 2)):532-4. PubMed ID: 1861294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment with oxybutynin hydrochloride of urinary incontinence and hyperactive bladder conditions in children].
    Aubert D; Cencig P; Royer M
    Ann Pediatr (Paris); 1986 Sep; 33(7):629-34. PubMed ID: 3777773
    [No Abstract]   [Full Text] [Related]  

  • 8. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quality of life of women with stress urinary incontinence with or without pollakiuria].
    Amarenco G; Marquis P; McCarthy C; Richard F
    Presse Med; 1998 Jan; 27(1):5-10. PubMed ID: 9767753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?
    Menarini M; Del Popolo G; Di Benedetto P; Haselmann J; Bödeker RH; Schwantes U; Madersbacher H;
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):623-32. PubMed ID: 17190372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
    López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E
    Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuropsychiatric adverse effects attributed to use of oxybutynin].
    t'Veld BA; Kwee-Zuiderwijk WJ; van Puijenbroek EP; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Mar; 142(11):590-2. PubMed ID: 9623118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose oxybutynin for the unstable bladder.
    Malone-Lee J; Lubel D; Szonyi G
    BMJ; 1992 Apr; 304(6833):1053. PubMed ID: 1586797
    [No Abstract]   [Full Text] [Related]  

  • 15. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride.
    Madersbacher H; Jilg G
    Paraplegia; 1991 Feb; 29(2):84-90. PubMed ID: 2023781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study.
    Hooper P; Tincello DG; Richmond DH
    Br J Urol; 1997 Sep; 80(3):414-6. PubMed ID: 9313659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of the use of oxybutynin hydrochloride (Pollakisu tablets) in the elderly].
    Uchibayashi T; Nakajima K; Nihino A; Hisazumi H
    Hinyokika Kiyo; 1991 Sep; 37(9):1077-85. PubMed ID: 1785418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxybutynin extended-release: a review of its use in the management of overactive bladder.
    Siddiqui MA; Perry CM; Scott LJ
    Drugs; 2004; 64(8):885-912. PubMed ID: 15059046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical oxybutynin chloride for relaxation of dysfunctional bladders.
    Brendler CB; Radebaugh LC; Mohler JL
    J Urol; 1989 Jun; 141(6):1350-2. PubMed ID: 2724432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
    Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
    Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.